Estrogen-only hormone therapy is tied to less Alzheimer’s damage in the brain, a study finds

A large new analysis has found that women who took estrogen-only menopausal hormone therapy later in life had markedly fewer hallmarks of Alzheimer’s disease in their brains and a lower risk of being diagnosed with dementia. The results, drawn from data on more than 21,000 women, land in the middle of a decades-long and often contradictory debate over whether hormone therapy helps or harms the aging brain. Researchers were careful to stress that the study shows an association, not proof that the treatment prevents disease.

The findings matter because dementia is far more common in women than in men, and menopause has long been suspected as one reason for that gap. The steep drop in estrogen that accompanies menopause coincides with changes in brain metabolism, and scientists have wondered for years whether replacing some of that lost hormone might protect neurons over the long run. This study offers one of the more detailed looks yet at what actually turns up in the brain tissue of women who used the therapy.

What the study measured

The analysis, published in the journal Neurology, combined two major datasets: a cohort in which participants’ brains were examined by autopsy after death, and a living cohort followed with brain imaging and clinical assessments. Together they included 21,462 female participants, with 2,959 of them undergoing autopsy at an average age of 82. That combination let researchers compare not just dementia diagnoses during life but the physical signatures of Alzheimer’s disease in the brain itself. The work was described by the Stanford team that led it as an effort to connect real brain pathology with hormone use rather than relying on diagnosis alone.

Those brain hallmarks are specific. Alzheimer’s disease is defined at the tissue level by two abnormal protein deposits: amyloid plaques that accumulate between neurons and tau tangles that form inside them. Autopsy allows pathologists to see and grade these directly, which is why the death-cohort portion of the study carried particular weight. A lower burden of plaques and tangles is not a symptom a patient reports; it is a measurable feature of the disease process.

The size of the association

Among the women studied, use of hormone therapy was linked to 39 percent lower odds of a dementia diagnosis and 35 percent lower odds of Alzheimer’s-related brain changes seen at autopsy, including those amyloid plaques and tau tangles. Those are substantial reductions, and the fact that they appeared in autopsy tissue, not just in clinical records, gave the researchers more confidence that they were seeing something real in the biology rather than an artifact of how dementia gets diagnosed.

Still, the numbers describe a correlation. As the researchers and outside experts noted, women who take hormone therapy may differ in other ways from those who do not, in health, wealth, access to care, or lifestyle, and those differences can influence dementia risk on their own. Coverage of the results, including a detailed account of the findings, underscored that the association, however strong, cannot by itself establish cause and effect.

Why estrogen alone, and not the combined form

A crucial detail is that the study focused specifically on estrogen-only therapy. Menopausal hormone treatment comes in two broad forms: estrogen given by itself, typically for women who have had a hysterectomy, and estrogen combined with a progestin, prescribed for women who still have a uterus because progestin protects the uterine lining. Earlier research had raised concern that the combined form might actually raise dementia risk, so isolating the estrogen-only group was deliberate.

That distinction helps explain why hormone therapy’s reputation for brain health has been so muddled. Trials that lumped the two formulations together, or that started treatment well after menopause, produced discouraging results in the past, feeding a widespread impression that the therapy was bad for cognition. Separating the formulations, and paying attention to when treatment begins, suggests the picture is more nuanced than a single yes-or-no answer.

What it does and does not settle

The researchers were explicit that their work does not demonstrate that hormone therapy can prevent dementia. An observational study, even a large one built partly on autopsy data, can reveal a strong pattern but cannot rule out every alternative explanation. Establishing cause would require randomized trials designed specifically to test brain outcomes, tracking women over many years, and those take time and considerable expense to complete.

For now, the practical takeaway is cautious. The study adds meaningful weight to the idea that estrogen-only therapy, at least in certain women and at certain times, is associated with less Alzheimer’s pathology, and it sharpens the questions future trials will need to answer. It does not amount to a recommendation that women take hormones to protect their memory. Decisions about menopausal hormone therapy still hinge on an individual balance of benefits and risks, from symptom relief to cardiovascular and cancer considerations, worked out between a patient and her physician rather than dictated by a single striking result.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview